Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 5/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | HTT | P42858 | 1/20 | 0.67 |
| ▸ | FAAH | O00519 | 12/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14593657 | 1.00 | EPHX1 (0.67) | EPHX1ALDH1A1HTTFAAHKMT2A | |
| SCHEMBL14593705 | 1.00 | EPHX1 (0.67) | EPHX1ALDH1A1HTTFAAHKMT2A | |
| SCHEMBL14593707 | 0.97 | EPHX1 (0.67) | EPHX1ALDH1A1HTTFAAHKMT2A | |
| SCHEMBL14593753 | 0.92 | EPHX1 (0.58) | EPHX1ALDH1A1HTTFAAHKMT2A | |
| SCHEMBL14593725 | 0.91 | EPHX1 (0.67) | EPHX1ALDH1A1HTTKMT2AEPHX2 | |
| SCHEMBL14593665 | 0.91 | KMT2A (0.70) | EPHX1ALDH1A1HTTKMT2AEPHX2 | |
| SCHEMBL6689381 | 0.91 | FAAH (0.56) | EPHX1ALDH1A1HTTFAAH | |
| SCHEMBL6697390 | 0.89 | CA12 (0.56) | EPHX1ALDH1A1HTTFAAH | |
| SCHEMBL7214953 | 0.88 | S1PR1 (0.57) | EPHX1ALDH1A1HTTFAAH | |
| SCHEMBL11033138 | 0.88 | EPHX1 (0.84) | EPHX1ALDH1A1HTTEPHX2HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7157601-B2 | Alkylated urea and triaminotriazine compounds and phase change inks containing same | XEROX CORPORATION (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157601-B2 | Alkylated urea and triaminotriazine compounds and phase change inks containing same | XEROX CORPORATION (US) | 2007-01-02 | — | — | US | disclosed |
| US-20060178531-A1 | Alkylated urea and triaminotriazine compounds and phase change inks containing same | XEROX CORPORATION | 2006-08-10 | — | — | US | disclosed |
| US-7087752-B2 | Alkylated urea and triaminotriazine compounds and phase change inks containing same | XEROX CORPORATION (US) | 2006-08-08 | — | — | US | disclosed |
| US-6860928-B2 | Alkylated urea and triaminotriazine compounds and phase change inks containing same | XEROX CORPORATION (US) | 2005-03-01 | — | — | US | disclosed |
| US-20040249210-A1 | Alkylated urea and triaminotriazine compounds and phase change inks containing same | XEROX CORPORATION | 2004-12-09 | — | — | US | disclosed |
| US-20040075723-A1 | Alkylated urea and triaminotriazine compounds and phase change inks containing same | XEROX CORPORATION | 2004-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178531-A1 | Alkylated urea and triaminotriazine compounds and phase change inks containing same | NR1H3, SIGMAR1, NCOR1 | EPHX1 3947/4885ALDH1A1 2509/4885HTT 2048/4885 |
| US-20040249210-A1 | Alkylated urea and triaminotriazine compounds and phase change inks containing same | NR4A1, NR0B1, RCOR1 | EPHX1 4300/4885ALDH1A1 2145/4885HTT 1168/4885 |
| US-20040075723-A1 | Alkylated urea and triaminotriazine compounds and phase change inks containing same | NR4A1, NR1I3, CCNY | EPHX1 4409/4885ALDH1A1 3012/4885HTT 2624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.